MegaMD Co. Ltd (133750) fair value: what the stock is really worth
As of Nov 6, 2026: fair value (intrinsic value) of MegaMD Co. Ltd stock KRW 2,776, price KRW 1,389, upside +99.8%, quality 63 out of 100. Rating: strongly undervalued. Calculated from audited financials with 24 of our 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 7, 2026.
How to read this chart
60‑month range 1,220 KRW – 6,214 KRW · fair‑value band 2,296 KRW – 3,470 KRW · the 1,389 KRW price screens below the 2,776 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 7, 2026.
Follow MegaMD Co. in your weekly email
Every Wednesday you see whether MegaMD Co. is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
MegaMD Co., Ltd. engages in the operation of educational institutions in South Korea. The company's education services specialize in infant, elementary, middle, and high school education, as well as adult entrance exams.
Show moreShow less
It is also involved in the operation of online lecture sites; and provision of information services. The company was founded in 2004 and is headquartered in Seoul, South Korea.
Stock analysis
MegaMD Co. Ltd (133750) currently trades at 1,389 KRW, while our model-based Fair Value estimate is 2,776 KRW, implying the stock looks roughly 50% undervalued today.
Show more
Valuation
Bull case: the DCF Models group reads highest at a median of 2,948 KRW per share, and 18 of the 24 models we run sit above the 1,389 KRW price.
Bear case: the Dividend Discount group reads lowest at 656.51 KRW, and 6 of the 24 models stay below the price. Data coverage for this calculation is high.
Scenario range: 2,296 KRW (bear) to 3,470 KRW (bull), the price of 1,389 KRW sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 63/100 (solid quality), in the Consumer Defensive sector.
Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.
MegaMD Co. Ltd reported revenue of 34.6B KRW in FY2025 versus 79.4B KRW in FY2021, a compound −18.8%/yr. Reported net income was 2.8B KRW in FY2025, compounding −19.5%/yr from FY2021.
Key figures
Market cap 30.7B KRW (≈ $22.7M) Micro · P/E ratio 9.8 · P/S ratio 0.87 · EPS (TTM) 142.29 KRW · Dividend yield 4.3% · Net margin 8.9% · Return on equity 4.8% · Return on assets (EBIT) 0.9% (5-year average).
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 44 out of 100 (low confidence).
What moves the price
The share trades about 27% below its 52-week high and 14% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Consumer Defensive peers we cover trades at 31% fair-value upside, at 100%, 133750 screens cheaper than that median.
Fair Value models
Bear2,296 KRWFair Value 2,776 KRWBull3,470 KRW
Price 1,389 KRW · Upside +99.8%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then (70.57 KRW per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.40/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−5.2%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−18.7%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−15.9%
Start year 2020 (pandemic). Over 10 years: −6.4% a year
Revenue growth 11 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−5.5%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years), in KRW ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in KRW: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
−6.3%
Earnings growth per share plus dividend.
Earnings per share, growth per year−10.6%
Dividend (yield on the price)4.3%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.−10.6% vs 3.5%, slowing
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.8% → 6%
Pace: the 5-year rate starts in 2020 (pandemic)
⚠ Revenue per share shrinking 9.5%/yr over ~7Y (margins intact) ⓘStructural-decline marker: revenue PER SHARE has fallen over the last decade (robust median trend, not a single year). Backtested across 2005 to 2017, such businesses trailed the market by about 2.5 percentage points per year. Display only: it does not change the fair value or the quality score.
Growth Forecast
Little optimism in the price
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
less than -40 %
The company could shrink this much every year for the next five years and today's price would still be justified.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Education & Training Services · 108 stocks
Beats the industry median on 10/13 measures
Overall it ranks above its industry peers.
Valuation
Quality Score63 · Above median
Fair Value upside+99.8% · Top 25%
Profitability
Return on equity (12 months)4.8% · Below median
Return on assets3.4% · Below median
Net margin (12 months)8.9% · Above median
Operating margin (12 months)12.6% · Above median
Growth and dividend
Revenue growth (quarter YoY)−9.0% · Bottom 25%
Dividend yield (12 months)4.3% · Above median
Valuation Multiplesvs Education & Training Services median · lower = cheaper
P/E (12 months)9.8× · Cheaper than median
P/B0.46× · Cheapest 25%
P/S (12 months)0.87× · Cheaper than median
Price / free cash flow (fiscal year)8.1× · Cheaper than median
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is MegaMD Co. Ltd (133750) overvalued or undervalued?
As of Nov 7, 2026, our model estimates a fair value of 2,776 KRW versus a price of 1,389 KRW, about +100% upside (undervalued).
What is the fair value of 133750?
Our model-based fair value for MegaMD Co. Ltd is 2,776 KRW (as of Nov 7, 2026), built from audited fundamentals. The current price: 1,389 KRW.
What is the quality score of 133750?
MegaMD Co. Ltd has a Quality Score of 63/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for MegaMD Co. Ltd (133750)?
Our model-based price target is the fair value of 2,776 KRW (as of Nov 7, 2026) from 24 valuation models. Cautious scenario 2,296 KRW, optimistic scenario 3,470 KRW. It is a calculation from audited fundamentals, not an analyst target.
What is the MegaMD Co. Ltd stock forecast for 2026?
Our models put fair value at 2,776 KRW, about +100% upside versus a price of 1,389 KRW (undervalued). Cautious scenario 2,296 KRW, optimistic scenario 3,470 KRW. The calculation is refreshed regularly with new filings.
What is the revenue of MegaMD Co. Ltd (133750)?
MegaMD Co. Ltd reported trailing-twelve-month revenue of about 35.2B KRW (latest available figure, as of Nov 7, 2026).
Does MegaMD Co. Ltd pay a dividend?
MegaMD Co. Ltd currently shows a dividend yield of 4.32% relative to its recent price (as of Nov 7, 2026).
How much is the dividend of MegaMD Co. Ltd (133750) and when is the ex-dividend date?
MegaMD Co. Ltd pays a dividend of 60.00 KRW per share a year, a dividend yield of 4.3%. The last ex-dividend date was Mar 26, 2026. The payout ratio is 42.2% of earnings. Free cash flow covers the dividend 2.85 times. Our assessment: Well covered. A low payout and the dividend is fully funded by free cash flow, a comfortable, sustainable dividend.
What growth is priced into MegaMD Co. Ltd (133750)?
For today's price to be fair in a discounted-cash-flow model, MegaMD Co. Ltd would have to grow free cash flow by less than minus 40 % per year for five years (discount rate 8.9 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew -15.9 % per year. As of Nov 7, 2026.
What discount rate (WACC) does the fair value of 133750 use?
Our models discount MegaMD Co. Ltd at 8.9 %: a base by market capitalisation (nano), damped by beta 0.42, country premium for South Korea. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For MegaMD Co. Ltd that is less than minus 40 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (8.9 %) and the same formula as our fair value.
How much growth has MegaMD Co. Ltd (133750) delivered so far?
Over the past 5 years revenue at MegaMD Co. Ltd grew -15.9 % a year. The price currently implies free-cash-flow growth of less than minus 40 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of MegaMD Co. Ltd (133750) growing?
The median revenue growth in the sector is +4.7 % a year. That is the yardstick for the growth priced into MegaMD Co. Ltd (less than minus 40 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of MegaMD Co. Ltd (133750)?
The free-cash-flow yield on the price is 12.30 %: that much free cash flow MegaMD Co. Ltd produces per unit of market value. When it exceeds the discount rate of our models (8.9 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of MegaMD Co. Ltd (133750)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For MegaMD Co. Ltd it is 2,776 KRW per share (as of Nov 7, 2026), against a price of 1,389 KRW. It is the blended result of 24 valuation models in 8 families (DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings).
Is MegaMD Co. Ltd stock overvalued or undervalued in 2026?
As of Nov 7, 2026, 133750 trades below its calculated fair value: price 1,389 KRW, fair value 2,776 KRW, a gap of about +100% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 133750?
No. The price is what the market pays today (1,389 KRW); the fair value is what the company's own numbers justify (2,776 KRW). For MegaMD Co. Ltd the two are 1,387 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is MegaMD Co. Ltd worth?
The market values MegaMD Co. Ltd at about 30.7B KRW (market capitalisation, as of Nov 7, 2026). Per share that is 1,389 KRW; our models calculate a fair value of 2,776 KRW per share.
What do the bullish and bearish scenarios say about 133750?
Our models span a range for MegaMD Co. Ltd: cautious scenario 2,296 KRW, base 2,776 KRW, optimistic 3,470 KRW per share (as of Nov 7, 2026, price 1,389 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 133750?
MegaMD Co. Ltd trades at a price-to-earnings ratio of 9.8 (as of Nov 7, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of 2,776 KRW is built from several models across several years. Median P/E at fiscal year-end, 8 fiscal years (2016 to 2025), reported earnings: 23.0. Other multiples: P/B 0.5, P/S 0.9, EV/EBITDA 3.0.
How solid is the balance sheet of MegaMD Co. Ltd (133750)?
Balance-sheet figures for MegaMD Co. Ltd (as of Nov 7, 2026): return on equity 4.8%. They feed the Quality Score of 63/100, which measures business quality independently of the share price.
How far is 133750 from its 52-week high?
MegaMD Co. Ltd trades at 1,389 KRW, about 27% below its 52-week high of 1,895 KRW and 14% above the low of 1,220 KRW (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of 2,776 KRW is for.
Which stocks are comparable to MegaMD Co. Ltd?
From the same area (Consumer Defensive) we also value New Oriental Education & Technology Group, Laureate Education, Inc, Covista Inc, Physicswallah Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is MegaMD Co. Ltd stock attractive at the current price?
The data as of Nov 7, 2026: price 1,389 KRW, calculated fair value 2,776 KRW (+100%), Quality Score 63/100, from 24 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 133750 calculated?
We run MegaMD Co. Ltd through 24 models from 8 families: DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of 2,776 KRW builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. MegaMD Co. Ltd currently trades 50% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of MegaMD Co. Ltd (133750)?
The closing price on Nov 6, 2026 was 1,389 KRW. Our model-based fair value is 2,776 KRW, about +100% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with MegaMD Co. Ltd right now?
The price is below even our cautious bear case (2,296 KRW). The market is more pessimistic than our downside scenario. Solid quality (63/100) at a price below fair value, the discount is the argument here, not the business quality.
Key figures of MegaMD Co. Ltd
How large is the market capitalisation of MegaMD Co. Ltd (133750)?
The market capitalisation of MegaMD Co. Ltd is 30.7B KRW (≈ $22.7M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of MegaMD Co. Ltd (133750)?
The price-to-sales ratio of MegaMD Co. Ltd is 0.87 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of MegaMD Co. Ltd (133750)?
Earnings per share at MegaMD Co. Ltd are 142.29 KRW (price ÷ EPS = P/E 9.8). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of MegaMD Co. Ltd (133750)?
The dividend yield of MegaMD Co. Ltd is 4.3% (payout 42.2%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of MegaMD Co. Ltd (133750)?
The net margin of MegaMD Co. Ltd is 8.9% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of MegaMD Co. Ltd (133750)?
The return on equity (ROE) of MegaMD Co. Ltd is 4.8% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of MegaMD Co. Ltd (133750)?
On an EBIT basis the return on assets of MegaMD Co. Ltd is 0.9% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of MegaMD Co. Ltd (133750)?
The operating margin of MegaMD Co. Ltd is 12.6% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at MegaMD Co. Ltd (133750)?
Revenue at MegaMD Co. Ltd is growing −9.0% versus a year earlier (3y avg −18.7%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at MegaMD Co. Ltd (133750)?
Earnings per share at MegaMD Co. Ltd are growing +49.1% versus a year earlier. How much earnings per share grew versus a year earlier.
Free · no account needed
Watch MegaMD Co. Ltd in the live analysis
One click puts MegaMD Co. Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Broad data
Nov 7, 2026